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 Abstract 
 
IMPACT OF FDAAA ON REGISTRATION, RESULTS REPORTING, AND 
PUBLICATION OF CLINICAL TRIALS EVALUATING NEW 
NEUROPSYCHIATRIC DRUGS APPROVED BETWEEN 2005 AND 2014 
 
Constance X. Zou, Jessica E. Becker, Adam T. Phillips, James M. Garritano, Harlan M. 
Krumholz, Jennifer E. Miller, Joseph S. Ross 
 
Center for Outcome Research and Evaluation, Department of Medicine, Yale University 
School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut 
 
  Evidence-based medicine (EBM) promotes the use of randomized controlled trials 
(RCTs) published in peer reviewed medical journals as the “gold standard”. However, up 
to 50% of the completed clinical trials are never published and trials with results in favor 
of studied interventions are 2-4 times more likely to have been published then those with 
non favorable results. Publication bias seems to be a particularly severe problem for 
RCTs evaluating newly approved brand-name neuropsychiatric drugs. Mandatory trial 
registration, and later results reporting, were proposed to mitigate selective clinical trial 
publication and outcome reporting. Congress enacted the FDA Amendments Act 
(FDAAA) on September 27, 2007 requiring the registration of all non-phase I clinical 
trials involving FDA-regulated medical interventions and results reporting for FDA 
approved drugs. It’s been 10 years since FDAAA enactment, the impact of FDAAA on 
the selective publication of clinical trials has not been studied. Our objective is to 






registration and results reporting, as well as with decreased publication bias of clinical 
trials evaluating new neuropsychiatric drugs. We conducted a retrospective cohort study 
of all efficacy trials supporting FDA new drug approval between 2005 to 2014 for 
neuropsychiatric indications. Trials were categorized as pre- or post-FDAAA based on 
initiation and/or completion dates as outlined by the statue. The main outcomes were the 
proportions of trials registered, proportions reported results in ClinicalTrials.gov, and the 
degree of publication bias. Publication bias was estimated using the relative risks pre- and 
post-FDAAA of both the publication of positive vs non-positive trials, as well as of 
publishing positive vs. non-positive trials without misleading interpretations. Registration 
and results reporting proportions were compared pre- and post-FDAAA using two-tailed 
Fisher Exact Test and the degrees of publication bias were compared by calculating the 
ratio of relative risks (RRR) for each period. Our study sample included 101 Pre-FDAAA 
and 41 Post-FDAAA efficacy trials supporting the FDA approval of 37 new drugs for 
neuropsychiatric indications between 2005 and 2014. Post-FDAAA trials were 
significantly more likely to be registered (100% vs 64%; P<0.001) and report results 
(100% vs 10%; P<0.001) than pre-FDAAA trials. Pre-FDAAA, positive trials were more 
likely to be published (RR=1.52; 95% Confidence Interval [CI]=1.17-1.99; P=0.002) and 
published without misleading interpretations (RR=2.47; Cl=1.57-3.73; p<0.001) than 
those with non-positive results. In contrast, post-FDAAA positive trials were equally 
likely to have been published (RR=1; Cl=1-1, p=NA), and published without misleading 
interpretations (RR=1.20; Cl=0.84-1.72; p=0.30). The likelihood of publication bias pre-
FDAAA vs. post-FDAAA was greater for publication of positive vs. non-positive trials 
(RRR=1.52; Cl=1.16-1.99; p=0.002) and for publication without misleading 
interpretations (RRR=2.06, Cl=1.17-3.61, p=0.01). The enactment of FDAAA was 






results on ClinicalTrials.gov, and with significantly lower degrees of publication bias 
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The Role of Randomized Controlled Trials in Modern Medicine  
  Randomized controlled trials (RCT) started to have profound impacts on the prac-
tice of medicine today since the rise of evidence-based medicine (EBM) , which has been 
defined as “the conscientious, explicit, and judicious use of current best evidence in mak-
ing decisions about the care of individual patients.” (1) However, it is difficult, to put 
one’s finger on what made EBM the haute couture, based on its name and such a defini-
tion. Some find it difficult to distinguish the phrase EBM from the word medicine itself. 
(2, 3) (3)(4–7)If one were to summarize the teaching of how-to-EBM textbooks and 
guides(14–18), EBM method describes an RCT based formula to answer hypothetical 
questions involving hypothetical patients with hypothetical diseases related to clinical 
care. The main agenda of the EBM campaign is to make sure that RCTs are the best evi-
dence and that only the RCT are good enough to rely on as the “gold standard” for  
“judging whether a treatment does more good than harm” (19)because they are “so much 
more likely to inform clinicians and so much less likely to mislead them” (than the alter-
natives).(20)(3)(21)  
  The success of EBM campaign has resulted in many parts of medicine being gov-
erned by RCTs through the Practice Guidelines, which are usually issued by medical pro-
fessional societies outlining best practices. These practice guidelines are welcomed by 
physicians who are believers of the power of RCT but find themselves incapacitated by 
the complexity of the method and the volume of the work involved in full EBM style in-
vestigation and calculation. The proponents of EBM may object to the idea that EBM en-








learn to speak the EBM fluently themselves and use it to guide their day to day practice. 
That could happen if the United States suddenly required graduate degrees in statistics for 
all medical school graduates; if the physicians have at least days between each appoint-
ment to perform one round of  rituals in full as outlined by the 500-hundred page long 
EBM bible; (21) and if there is a sudden change of US malpractice law. The truth is the 
physicians cannot afford the time or the effort to perform EBM on their own. When they 
do try, it usually means a quick PubMed search followed by skimming through the ab-
stracts of a few randomly selected publications of RCTs. They could not afford the lux-
ury sometimes to disobey the order of the “best practice” as outlined in the practice 
guidelines, even when they have good reasons to believe it inappropriate for a given set-
ting. They may lose bonuses tied to meeting “quality measures”, which are frequently 
based on guidelines, or worse, they can be sued for transgressing the norm as definied by 
their professional societies even though it was suppose to be a suggestion.   
Practice guidelines are being used in the malpractice arena to define a credible standard 
of care to measure the accused physician for an alleged problem addressed. This may 
occur despite a medical society's disclaimer that they are not intended, nor devised, for 
that purpose. (22)  
 
 
RCT, Gold Standard with an Achille’s Heel 
  The EBM formula relies on RCTs published in the literature. The problem is as 
many as 50% of completed clinical studies were never published (23–42)What’s more, 
trials with non-positive results were significantly more likely to remain unpublished than 
trials with positive results and negative results were often manipulated to appear positive.  
(39, 43–46) 
Experience has shown that such study reports do not always contain a complete, or en-








deliberate deception) is unusual. However, incompleteness, lack of clarity, unmentioned 
deviation from prospectively planned analyses, or an inadequate description of how criti-
cal endpoint judgments or assessments were made are common flaws. (47) 
 
  Because studies were usually considered positive when whatever proposed new in-
tervention works better than a control, publication bias leads to perceived efficacy. EBM 
informed clinical practice based on half of the whole truth can result in inappropriate en-
thusiasms for what’s new. Many considered the problems of nonpublication and untruth-
ful publication to be particularly severe among trials evaluating newly approved brand 
name neuropsychiatric drugs.(48) Clinical studies supporting approved drugs for neuro-
psychiatric indications, such as paroxetine (Paxil) (49), reboxetine (Edronax ) 
(50)gabapentin (Neurontin) (51), and lamotrigine (Lamictal) (52), have been identified as 
being subject to underreporting. Data demonstrating these drugs to be potentially ineffec-
tive for approved indications or suggesting harm were not publicly disclosed until the 
pharmaceutical companies’ internal documents were reviewed during legal proceedings 
(53, 54) 
  Ten years ago, if a psychiatrist were to use the EBM method to calculate and com-
pare the effect size of any of the one dozen antidepressants approved in the previous sev-
eral decades, he or she would find only good news—all of the published trials showed the 
drugs to be effective, but in fact only half of the completed trials were. The physician 
would overestimate the effect size of each drug for about 30%. (28)Take one of these an-
tidepressants Serzone (nefazodone) for example, which was approved by the FDA in 
1994. When the drug was just approved, Bristol-Myers called it a "significant" addition 
to the numerous antidepressants with an “additional boost, fewer side-effects—and a 
lower price.”(55) It was speculated that the sales of this drug contributed to the fact that 








on FDA documents was only 0.26. Effect size measures the magnitude of difference be-
tween a given drug and the placebo. 0.2-0.5 is small difference, 0.5-0.8, medium, and 
0.8-1, high. 0.26 means the difference between nefazodone and sugar pills are small. Be-
cause its effective size based on the published trials was 69% higher, EBM practice based 
on published RCTs would conclude that the drug seem to have a moderate effect.  (28) It 
is also worth noting this drug was associated with severe liver toxicity and death and was 
pulled from the market in 2004. (57–59)  
  Similarly, among trials evaluating drugs indicated for anxiety (23), and psychotic 
disorders (60) that were first approved by the U.S. Food and Drug Administration (FDA) 
in recent decades, 80-90% of trials with negative or equivocal results were either not pub-
lished or were published in a misleading manner to suggest a positive result, while nearly 
100% of trials with positive results were published. 
 
RCT, Gold Standard or Gold Trojan Horse? 
  Many feel that this new paradigm brought by EBM based on RCT is doomed to fail 
because the industry can and will harness the power of RCT for the benefit of the few. (2, 
3, 61–73) 
  In the perfect world pictured by the proponents of EBM, RCTs are performed by 
disinterested researchers who are driven only by the desire to further truth,to improve 
care, and to reduce waste. In reality, most large RCT are sponsored by the industry as 
business strategy. It is unrealistic to expect that they will always choose to protect the 








States spends on healthcare each year, of which 17% were for prescription drugs. (74)  
  Because of high cost of new drug development, high risk of failure, and high poten-
tial financial gain, conflicts of interest is a particularly serious problem for RCT evaluat-
ing new drugs. With few exceptions, for profit industry are the primary funders of clinical 
trials because of the high cost associated with conducting early phase clinical trials to 
evaluate drugs that had never been used in humans: Phase II trials can cost up to $20 mil-
lion dollars, while Phase III, up to $50 million each. On average, the cost to run clinical 
trials to support the FDA approval of a new drug for a single indications is about 200 mil-
lions dollars. In order for the drug company to profit, not only they need to recover the 
astronomical cost invested in the drug targest that received approval, but also those that 
did not, which happens 2 to 50 times more often. (75, 76) (77) 
 
 FDAAA: Mandatory Registration and Results Reporting  
  What can be done to prevent the results of completed trials from being swept under 
the rug? Publication has always been and will likely remain voluntary, but if the proto-
cols and results of all clinical trials can be found through a publicly accessible, central-
ized trial registry, it would be difficult for the sponsors to withhold trials with unfavora-
ble results or to introduce post hoc analysis to encourage positive interpretations of the 
results. Additionally, Journal editors, peer reviewers, and interested members of the pub-
lic could cross reference the results submitted by the sponsors and investigators for publi-
cation. 
  In 1997, Congress passed the FDA Modernization Act (FDAMA), which mandated 
the first U.S.-based public registry ClinicalTrials.gov  in 2000 by the National Institute of 








issued a policy requiring trial registration as a condition of publication in member jour-
nals.De Angelis et al., 2009, #257} Nonetheless, FDAMA only required registration of a 
small number of trials, while the ICMJE recommendation was only followed on a volun-
tary basis and still permitted publication of unregistered trials. (78) (79)  
  In 2007, Congress passed the FDA Amendments Act (FDAAA). At the time 
FDAAA was applicable to essentially all non-phase I interventional studies involving 
FDA-regulated drugs, biological products, or devices with manufacture site or trial site 
based in the United States. FDAAA mandated that sponsors and investigators register all 
applicable trials in ClinicalTrials.gov prior to subject enrollment, and report results to 
ClinicalTrials.gov within 30 days post approval of the indication being studied. FDAAA 
is applicable to trials that began after September 27th, 2007 and to earlier trials that were 
still ongoing as of December 26th, 2007. Inappropriately delayed registration and results 
reporting, as well as reporting of false results, are punishable by fines of up to $10,000 
per day and can lead to withholding of funding from studies receiving federal support.  
  It has now been ten years since FDAAA was enacted. Its impact on clinical trial 
registration, results reporting, and publication bias has largely remained undetermined. 
(41)Recently we demonstrated that FDAAA was associated with increased registration 
and publication of clinical studies in another study involving new drugs approved to treat 
cardiovascular disease and diabetes (CXZ performed data validation and contributed to 
the final editing of the manuscript for publication). (80)However, no study has focused 
on trials involving drugs treating neurological and psychiatric conditions, an area for 









Statement of Purpose 
 
  We conducted a retrospective cohort study using efficacy trials that were submitted 
to and reviewed by the FDA for the approval of new drug applications (NDA) between 
2005 and 2014 for the treatment of neurologic and psychiatric conditions. Our objective 
is to compare the rate of registration, results reporting, and the degree of publication bias 
for efficacy trials involving newly approved drugs treating neurologic and psychiatric 
conditions before and after the enactment of FDAAA. For each trial, we determined 
whether a trial is pre- or post-FDAAA based on trial initiation and/or completion dates, 
as well as their registration, results reporting, and publication status, Prior to conducting 
this study, we put forth the following hypotheses:  
 
1. There is an association between the FDAAA status, and the likelihood of trial 
registration on ClinicalTrials.gov.  
2. There is an association between the FDAAA status, and the likelihood of trial 
results reported to ClinicalTrials.gov.  
3. There is an association between the FDAAA status and the degree of publica-
tion bias. 
The aim of this study was three fold: (1) to assess the impact of FDAAA on selective reg-
istration and publication of efficacy trials supporting new drugs approved by the FDA to 








among trials evaluating newly approved neuropsychiatric drugs, and (3) to inform ongo-













  Data were obtained from three sources: Drugs@FDA , ClinicalTrials.gov and 
PubMed’s listing of Medline-indexed journals. Drugs@FDA is a public database 
maintained by the FDA, providing access to regulatory actions and documents issued for 
each drug approved by the agency. ClinicalTrials.gov is a public clinical trial registry 
database maintained by the National Library of Medicine at the NIH (U.S. National 
Library of Medicine 2018). PubMed’s list of Medline-indexed journals includes more 
than 5,500 biomedical journals. 
 
Novel Therapeutics Approved for Treating Neurological and Psychiatric Disorders, 
2005-2014 
  The Center of Drug Evaluation and Research (CDER), which is part of the FDA, 
provides annual reports summarizing all New Drug Applications (NDAs) approved in 
each year (U.S. Food and Drug Administration). We downloaded the reports from 2005 
to 2014, when available, and otherwise searched Drugs@FDA for those NDAs that were 
approved to treat neurologic and psychiatric disorders. Our study sample began with 
drugs approved in 2005 to align with our prior work (Downing, Aminawung et al. 2014) 
and because an earlier seminal study on the topic examined all antidepressants approved 
through 2004 (Turner, Matthews et al. 2008); we chose to exclude drugs approved after 
December 2014 to ensure that at least 24 months had passed between drug approval date 
and the date when we concluded the final search for the registration record, reported 








indication, orphan status, priority review status, accelerated approval status, sponsor, and 
approval date.  
   CXZ performed all of the above data collection in the summer of 2016. JSR, as the 
principle investigator, reviewed with CXZ the lists of approved NMEs and BLAs 
between 2005 and 2014 to ensure that all new drugs approved with neuropsychiatric 
indications were included in our sample. JSB, randomly selected 4 drugs using an online 
randomizer and validated the data collected for those 4 drugs.  
 
Efficacy Trials Supporting FDA New Neuropsychiatric Drug Approval 
  As described in a comprehensive tutorial for how to use the Drugs@FDA (Turner 
2013), we downloaded the relevant FDA files for each NDA from Drugs@FDA, 
including the approval letters, summary reviews, clinical reviews, and statistical reviews. 
Among these files, we searched for clinical trials evaluating the efficacy of the drugs 
under review. We included only trials for which the FDA discussed and characterized 
results, based on the assumption that these trials influenced the FDA’s decision to 
approve the study drug for the proposed indication. We excluded ongoing trials, phase 
I/safety-only trials, expanded access trials, terminated and withdrawn trials without 
enrollment, and trials evaluating indications different than that for which the drugs were 
originally approved. We also excluded failed trials. Failed trials were determined by the 
FDA and the results of failed trials are invalid. For each included trial, we recorded the 
following characteristics: pivotal status, phases, sponsors, study sites, trial length, 
randomization, blinding, types of control, description of the treatments, arms of the 
investigational drugs, enrollment numbers, and the primary efficacy endpoints. A pivotal 








support the safety and effectiveness evaluation of the medical product for its intended 
use” (2013). Pivotal status was frequently assigned prospectively by FDA, occasionally 
assigned retrospectively by the FDA, or at times not assigned by FDA and thus 
determined using a previously described method. (Downing, Aminawung et al. 2014) All 
searches and data collection were done by CXZ between June 2015 and October 2015. 
JSB validated the data collected associated with previously randomly selected 4 NDAs.  
 
Determination of FDAAA Status 
  At the time when. FDAAA was enacted in 2007, it applied to trials that were 
initiated after September 27th, 2007, as well as to trials initiated earlier but still ongoing 
as of December 26th, 2007. Based on this, FDAAA applicable trials were categorized as 
post-FDAAA, while trials that were initiated or completed prior to the cut-off dates were 
categorized as pre-FDAAA. All coding was done by CXZ in the summer of 2015. JSB 
validated the data collected associated with previously randomly selected 4 NDAs.  
 
Determination of Registration and Results Reporting Status on ClinicalTrials.gov 
  To determine whether trials were registered and reported results on 
ClinicalTrials.gov, one investigator (CXZ) performed the initial search using the 
following terms and their combination: generic, or brand names of the study drugs, drug 
indications, trial IDs, trial acronyms, numbers of participants randomized, comparators, 
and study time frames. All searches were done by CXZ between the summer of 2015. 
JSB validated the data collected associated with previously randomly selected 4 NDAs. 








investigator (JEB) independently performed a second round of searches. No new records 
were identified. 
 
Determination of Publication Status 
  To determine whether trials were published, we searched PubMed for full-length 
publications using the same terms as we did for the registration record. Among identified 
publications, abstracts and conference reports were excluded. Publications reporting 
multiple trials, such as reviews and meta-analyses were also excluded unless the results 
of each trial were analyzed and discussed individually in the level of detail as one would 
expect from a full-length publication. When the search terms returned too many similar 
entries in PubMed, we used Google Scholar to narrow the results. Google Scholar has the 
advantage that it can search among the full texts of publications hosted by a variety of 
online database or platforms, while for many journals, especially those that require paid 
access, PubMed searches only among the title and abstracts. All searches were done by 
CXZ between the summer of 2015 and the spring of 2016. JSB validated the data 
collected associated with previously randomly selected 4 NDAs. For trials that were not 
able to be matched with any registration record, a second investigator (JEB) 
independently performed a second round of searches. No new records were identified. 
 
Interpretation of Trial Results: Publication vs. FDA 
  Trials were classified as positive, negative, or equivocal based on the FDA’s 
interpretation of the results as described in Additional File 1. The classification was 
based on whether the primary outcome(s) achieved statistical significance while taking 








regarding whether or not the findings provide support for the efficacy claim of the study 
drugs. Published trial results were categorized similarly based on whether the primary 
outcomes achieved statistical significance according to the authors’ analysis while taking 
into considerations the authors’ conclusions in the abstract section. Trials with equivocal 
or negative results were grouped together as non-positive trials for purposes of 
calculating publication bias.  
  All data collection was done by CXZ between the summer of 2015 and the spring 
of 2016. JSB validated the data collected associated with previously randomly selected 4 
NDAs. For trials that were not able to be matched with any registration record, a second 
investigator (JEB) independently performed a second round of searches. No new records 
were identified. 
 
Validating the Published Interpretations 
  We validated the interpretations of the trial results made by the study 
investigators for each publication using the interpretations made by the FDA medical 
reviewers found in the FDA approval package as the gold standard. Both the conclusions 
in the abstract and the main text of the publications were validated. The two were 
considered in agreement if the interpretations were both categorized as positive, negative 
or equivocal, and no major contradictions existed between the two statements. As an 
example of contradiction between two sources: the published interpretation of trial 02 of 
milnacipran (Savella) concluded that “both doses (100 and 200 mg/d) were associated with 
significant improvements in pain and other symptoms.” (81)  This was considered different from 
the statement made by the FDA in the summary review documents, which stated that “[the] 








(Savella) on pain….(treatment effect) was driven by the patient global response outcome rather 
than the pain or function outcome…when studied in isolation, statistically significant treatment 
effects for pain and function were not demonstrated.” (82) All coding was done by CXZ in the 
summer and fall of 2016. JSB validated the coding associated with the previously 
selected 4 drugs. Due to the interpretive nature of this comparison, two additional 
investigators (JEB and JSR) reviewed all instances where there was disagreement 
between the FDA’s and the authors’ interpretation. 
 
Calculating the Degree of Publication Bias 
  We calculated and compared two different measures of publication bias between 
pre- and post-FDAAA trials. First, we estimated the relative risk of publication of 
positive vs non-positive trials in each period. Second, we estimated the relative risk of 
publishing positive vs non-positive trials without misleading interpretations in each 
period. Thus, publication bias was calculated as the ratio of relative risks (RRR) pre-
FDAAA vs post-FDAAA.  CXZ completed the data analysis in fall 2017 and JSR 
performed validation of the analysis.  
 
Data Collection and Data Validation 
  Registration status, results reporting status, publications status, and publication-
FDA interpretation agreement were validated as described previously. We performed a 
quality control for the rest of the data set, many of which were collected but not reported 
for purposes of this study. A second investigator (JEB) re-collected all data elements 
obtained for a random 10% sample of the included new drug approvals, using an online 








elements collected by the two investigators, the rate of agreement was 99.6% and 
disagreements were resolved through consensus.  
 
Data Analysis 
  We used descriptive statistics to characterize the proportions of trials that were 
registered and reporting results on ClinicalTrials.gov. We used two-tailed Fisher Exact 
tests to compare the proportions among pre- and post-FDAAA trials. Analysis was 
performed using Epi Info Companion App for iOS (3.1.1) (Centers for Disease Control 
and Prevention [CDC]; Atlanta, GA) , as well as with MedCalc online statistical software 
(2016), supplemented using an online program written by Hutchon (Hutchon 2015) to 
calculate the RRRs to estimate both measures of publication bias.  












Characteristics of the Neuropsychiatric Drugs Approved between 2005-2014 
  Between January 1st, 2005 and December 31st, 2014, 37 new drugs were approved 
by the FDA for the treatment of neuropsychiatric conditions, of which 23 (62%) were 
approved for neurological conditions and 14 (38%) for psychiatric disorders, which 
included 3 drugs for substance-use related conditions (Table 1). Among the 37 approved 
drugs, 34 (92%) were pharmacologic therapies, 3 (8%) were biologics; orphan status was 
granted for 9 (24%), priority review status for 6 (17%), and accelerated approval for 1 
(3%)   
 
Table 1. New Drug Applications (NDA) Approved by the FDA between 2005 and 2014 
with Indications for Neurologic and Psychiatric Conditions. 
 
 










Pfizer Smoking cessation 2006 
Azilect Rasagiline 
Mesylate 
Teva Parkinson’s disease 2006 






New River Attention deficit hyperactivity disorder 2007 
Neupro Rotigotine Schwarz Bi-
oscience 
Parkinson’s disease 2007 
Pristiq Desvenlafax-
ine Succinate 
Wyeth Major depressive disorder 2008 
Relistor Methylnaltrex-
one Bromide 
Progenics Opioid-induced constipation 2008 
Xenazine Tetrabenazine Prestwick Huntington's disease 2008 
Vimpat Lacosamide Schwarz Bi-
oscience 

































Cervical dystonia 2009 








Bipolar I disorder 2009 
Sabril Vigabatrin Lundbeck 
Inc 
Complex partial seizure disorder 2009 
Qutenza Capsaicin Neurogesx 
Inc 
Neuropathic pain 2009 
Ampyra Dalfampridine Acorda 
Therapeu-
tics Inc 






Cervical dystonia and Blepharospasm 2010 
Gilenya Fingolimod Novartis 
Pharmaceu-
ticals Corp 



















Restless legs syndrome 2011 
Potiga Ezogabine Glax-
oSmithKline 
Partial seizure disorder 2011 
Onfi Clobazam Lundbeck 
INC 
Seizures associated with Lennox-Gastaut 
syndrome 
2011 
Aubagio Teriflunomide Sanofi 
Aventis US 
LLC 
Multiple sclerosis 2012 


























Partial seizure disorder 2013 
Hetlioz Tasimelteon Vanda Phar-
maceuticals 
Inc 
Non-24-hour sleep-wake disorder 2014 
Northera Droxidopa Chelsea 
Therapeu-
tics Inc 












Multiple sclerosis 2014 
Movantik Naloxegol Astrazeneca 
Pharmaceu-
ticals LP 
Constipation s/p opioids 2014 
Note: INN= International nonproprietary name; NDA=New Drug Application; 
ADHD=Attention deficient hyperactivity disorder; please refer to the drug label for full 
description of each drug indication. 
 
Clinical Trials Supporting FDA Approval 
          There were 142 efficacy trials that supported the approval of these 37 
neuropsychiatric drugs (Figure 1), of which 101 (71%) were categorized as pre-FDAAA 
and 41 (29%) as post-FDAAA. All 142 trials were funded by industry and 105 (74%) 
were phase III, 33 (23%) phase II, and 4 (3%) phase II/III. In addition, the results of 107 
(75%) of the trials were interpreted by the FDA to be positive, 17 (12%) as equivocal, 
and 18 (13%) as negative (Table 2). 
 
 
Clinical Trial Registration and Results Reporting 
  FDAAA was followed by significantly greater proportions of trial registration and 








ClinicalTrials.gov, while 100% (41 of 41) of post-FDAAA trials were registered 
(P<0.001; Figure 2). Similarly, pre-FDAAA, 10% (10 of 101) of clinical trials reported 
results on ClinicalTrials.gov, while 100% (41 of 41) of post-FDAAA trials reported 
results (P<0.001; Figure 2); the results of 32 of 41 (78%) FDAAA trials were reported 
within 30 days of drug approval. 
 
Publication and Published Interpretations 
  Pre-FDAAA, among 72 positive trials, none were unpublished nor published with 
misleading interpretation. In contrast, among 29 non-positive trials, 10 (34%) were not 
published and 7 (24%) were published with misleading interpretations. Post-FDAAA, 
among 35 positive trials, again none were unpublished and none were published with a 
misleading interpretation. In addition, among 6 non-positive trials, none were 
unpublished and only 1 was published with a misleading interpretation. (Figure 3) The 
publications of the following new drugs had misleading interpretations: Droxidopa 
(Northera) of Chelsea Therapeutics, Dalfampridine (Ampyra) of Acorda Therapeutics, 
Iloperidone (Fanapt) of Vanda Pharmaceuticals, Milnacipran Hydrochloride (Savella) of 
Forest Research and Cypress Bioscience, and Rulfinamide (Banzel) of Novartis (Box 1). 
 
 
Table 2. Characteristics of 142 Efficacy Trials Supporting FDA Approval of NDA for 
Neuropsychiatric Conditions, 2005-2014. 
 





ported (%) No. Published (%) 
          
  (n=142)       
FDAAA Applicabil-
ity         








Post-FDAAA 41 (29%) 41 (100%) 41 (100%) 41 (100%) 
Pivotal Status         
Pivotal 92 (65%) 78 (85%) 40 (43%) 90 (98%) 
Non-Pivotal 50 (35%) 28 (56%) 11 (22%) 8 (84%) 
Study Location         
All United States 65 (46%) 50 (77%) 14 (22%) 61 (94%) 
Some United States 54 (38%) 41 (76%) 29 (54%) 48 (89%) 
None United States 23 (16%) 15 (65%) 8 (35%) 23 (100%) 
Study Phase         
Phase II 33 (23%) 17 (52%) 7 (21%) 28 (85%) 
Phase III 105 (74%) 87 (83%) 44 (42%) 102 (97%) 
Phase II/III 4 (3%) 2 (50%) 0 (0%) 2 (50%) 
Randomization         
NA (single-group) 5 (4%) 2 (40%) 0 (0%) 5 (100%) 
Randomized 136 (96%) 103 (76%) 51 (37%) 126 (93%) 
Nonrandomized 1 (1%) 1 (100%) 0 (0%) 1 (100%) 
Blinding         
Double-Blinded 135 (95%) 102 (76%) 51 (37%) 125 (92%) 
Open-Label 7 (5%) 4 (57%) 0 (0%) 7 (100%) 
Comparators         
Placebo Only 94 (66%) 70 (74%) 42 (45%) 86 (91%) 
Active Comparator 
Only 8 (6%) 5 (63%) 1 (13%) 7 (88%) 
Placebo and Active 
Comparator 29 (20%) 23 (79%) 6 (21%) 28 (97%) 
Lower-Dose Com-
parator Only 4 (3%) 4 (100%) 2 (50%) 4 (100%) 
No comparator 7 (5%) 4 (57%) 0 (0%) 7 (100%) 
 Note: FDAAA=Food and Drug Administration Amendments Act 
 
 
Table 3. Publication and Publication-FDA Agreement of Trials Supporting FDA 
Approval of NDAs with Neuropsychiatric Indications with Positive, Equivocal, and 
Negative Results.  
 
 Pre-FDAAA Post-FDAAA 
 FDA Interpretation of the Trial Results, No. (%) 
FDA Interpretation of the Trial Re-































0 (0%) 5 (31%) 2 (13%) 0 (0%) 1 (100%) 0 (0%) 
Not published 0 (0%) 2 (13%) 8 (62%) 0 (0%) 0 (0%) 0 (0%) 
Notes: Trials were classified as positive, negative, or equivocal based on the FDA’s 
interpretation of the results. Published interpretation of the trial with the FDA’s 
interpretation for each trial. The two were considered in agreement if the interpretations 
were both categorized as positive, negative or equivocal, and no major contradictions 
existed between the two statements. Negative and equivocal trials were combined into a 
single group as non-positive trials when calculating publication bias. 
 
Box 1 Examples of Trials Published with Interpretations Disagreeing with the 
Interpretations of the FDA medical reviewers 
 
 
FDA and Published Interpretations Not in Agreement 
 
Example #1  
 
Trial ID: Droxidopa (Northera) 301 
 
FDAAA Status: Post-FDAAA 
 
Sponsor: Chelsea Therapeutics 
 
FDA interpretation: Equivocal. "These results were considered to be implausible, and quite 
remarkable, different from all other data....1) If data from Site 507 were deemed acceptable, that 
would mean that the dossier included a single positive study. But with only 1 positive study and 
one site disproportionately responsible for the favorable treatment effect, the data would not 
constitute sufficient evidence of efficacy upon which to base an approval action. 2) If data from 
Site 507 were deemed inadmissible, then Study 301 was not positive; none of the studies were 
positive.” (83) 
 
Published interpretation: Positive. “"In patients with symptomatic nOH, droxidopa improved 
symptoms and symptom impact on daily activities, with an associated increase in standing 
systolic BP, and was generally well tolerated published the analysis per protocol.” (84) 
 
Example of Contradicting Interpretation #2 
 
Trial ID: Milnacipran Hydrochloride (Savella) 02 
 









Sponsor: Forest Research Institute and Cypress Bioscience 
 
FDA interpretation: Negative “[The] analysis of the ‘pain only’ responders does not indicate 
that there is a significant effect of MLN (Savella) on pain…. (treatment effect) was driven by 
the patient global response outcome rather than the pain or function outcome…when studied in 
isolation, statistically significant treatment effects for pain and function were not demonstrated.” 
(82) 
 
Published interpretation: Positive. “both doses (100 and 200 mg/d) were associated with 
significant improvements in pain and other symptoms.” (81) 
 
Example of Contradicting Interpretation #3 
 
Trial ID: Rufinamide (Banzel) AE/ET1 
 




FDA interpretation: Equivocal. FDA conclusion in summary review “Dr. Siddiqui noted that 
the sponsor had included the placebo group in its dose response analyses. Further, he noted that 
the dose groups were coded inappropriately (non-proportional to the actual dose). When the 
doses were coded proportionally to the actual dose in his dose-response analysis, and placebo 
was excluded, the p-value for the dose response slope was 0.086, implying none of the dose 
differed materially.” (85) 
 
Published interpretation: Positive. The author concluded in the abstract of the publication that 
“in the linear trend of dose response for seizure frequency per 28 days in the double-blind 
treatment phase was statistically significant in favor of rufinamide (p=0.003).” (86) 
 
Example of Contradicting Interpretation #4 
 
Trial ID: Milnacipran Hydrochloride (Savella) 031 
 
FDAAA Status: Pre-FDAAA 
 
Sponsor: Forest Research Institute and Cypress Bioscience 
 
FDA interpretation: Equivocal. The FDA medical reviewer in more than one places in the 
review emphasized that this trial fail to demonstrate effect as far as pain is concerned: “analysis 
of the ‘pain only’ responders does not indicate that there is a significant effect of MLN(Savella) 
on pain” and the treatment effect is “driven by the patient global response outcome rather than 
the pain or function outcome, when studied in isolation, statistically significant treatment effects 
for pain and function were not demonstrated”. In the risk benefit section of the summary review, 
the FDA again stated that "an unusual finding in this application is that, while the product 
appears to be effective when measured according to a prespecified responder definition, the 
results on the individual components of that responder definition, pain, function and a patient 
global evaluation, were not consistently statistically significant in the post-hoc analyses 
performed by the clinical/statistical review team. In particularly, the dominant feature of FM is 








statistically significant treatment effect for Savella (milnacipran), on the pain endpoint in either 
of the clinical trials." (82) 
 
Published interpretation: Positive. For trial 02 of milnacipran (Savella), the author of the 
publication concluded in the abstract that “both doses (100 and 200 mg/d) were associated with 
significant improvements in pain and other symptoms.” (87) 
 
Example of Contradicting Interpretation #5 
 
Trial ID: Iloperidone (Fanapt) 3000 
 
FDAAA Status: Pre-FDAAA 
 
Sponsor: Vanda Pharmaceuticals Inc 
 
FDA interpretation: Negative. “Thus, either approach to defining the sample for this study 
(whether it's FDA preferred or sponsor preferred) yields a negative result for iloperidone. With 
the sponsor's preferred analysis including all randomized patients, the superiority of haloperidol 
(active comparator) over the primary iloperidone (study drug) group (8+12mg) is statistically 
significant. This study, therefore, provides no support for iloperidone (study drug) but does 
suggest the statistically significant superiority of haloperidol (active control) over iloperidone 
(study drug).”  FDA reviewer also pointed out that the protocol of 3000 specified that no 
comparison of individual doses against place can be done unless the combined group 
12mg+8mg are shown to be significant, since the combined dose was not significant, then no 
individual dose comparison can be done, and the study is negative.” (88) 
 
Published interpretation: Positive. Publication concluded that 3000, 3004 and 3005 are all 
positive. The positive conclusion for 3000 was partially supported by comparing the outcomes 
of individual doses against placebo, a practice not supported by the protocol as pointed out the 
FDA reviewer Publication also did not comment on the fact that the study drug was less 
effective than the active control. Also, in the abstract session is the mentioning of other analysis. 
"Additional analysis in patients who received active treatment for at least 2 weeks indicated 
comparable efficacy score reductions at 6 weeks for patients receiving iloperidone 20 to 24 
mg/d versus those receiving haloperidol or risperidone". The publication stated, at the end of the 
abstract that "These trials indicate that iloperidone is effective for the treatment of 
schizophrenia." (89) 
 
Example of Contradicting Interpretation #6 
 
Trial ID: Iloperidone (Fanapt) 3004 
 
FDAAA Status: Pre-FDAAA 
 
Sponsor: Vanda Pharmaceuticals Inc 
 
FDA interpretation: Equivocal. "….... we still do not find this study an acceptable source of 
evidence. Although the results for both dose groups in the all-randomized patients’ analysis are 
positive, there is a striking difference in outcomes for the schizophrenic (intended indication) 
and the schizoaffective (not intended indication) subgroups. The analysis focusing only on the 
schizophrenic subgroup is not even close to positive for either dose group (p=0.306 for 10-








think the data for that trial are fatally pathological, and one cannot reasonably pool data from the 
schizophrenic and schizoaffective subgroups. It is not that I fundamentally object to polling data 
from schizophrenic and schizoaffective patients (we have accepted this approach many times in 
the past), but for this study, where the positive findings in the schizoaffective patients is by the 
sponsor's own admission an 'anomaly,' there is no justification for such a pooling. Thus, I find 
this study uninterpretable.” (88) 
 
Published interpretation: Positive. Same as 3000. "These trials indicate that iloperidone is 
effective for the treatment of schizophrenia." (89) 
 
Example of Contradicting Interpretation #7 
 
Trial ID: Iloperidone (Fanapt) 3005 
 
FDAAA Status: Pre-FDAAA 
 
Sponsor: Vanda Pharmaceuticals Inc 
 
FDA interpretation: Equivocal. FDA noted that” the effect size observed in Study 3005 was 
greater in active control than in both doses of iloperidone”. And that” the observation in study 
3005 that the positive effect for iloperidone over placebo was coming almost entirely from the 
non-US sites.”  The reviewer, in summarizing the findings in study 3005, pointed out that stated 
that the data collected from the US sites for study 3005 were uninterpretable I am persuaded by 
the sponsor's argument that the lack of efficacy in the US sites for study 3005 should not rule 
out this study as a source of evidence. As they point out, risperidone also failed in the US sites, 
and thus, data from these sites is simply uninterpretable.” The conclusion of the FDA was “For 
study 3005, only the analysis focused on the schizophrenic subgroup shows superiority of 
iloperidone over placebo. In the sponsor's preferred analysis, iloperidone fails to show 
superiority to placebo and, at the same time, risperidone appears to be statistically significantly 
superior to iloperidone.” (88) 
 
Published interpretation: Positive. Publication concluded that one of the doses in study 3005, 
20–24 mg/d [P = 0.010]). "Active controls were also significantly more effective than placebo in 
each trial, thus validating the trials... These trials indicate that iloperidone is effective for the 
treatment of schizophrenia."  No comparison was drawn between the active control with 
iloperidone. No statement was made regarding the data from the US study sites were 
uninterpretable.” (89) 
 
Example of Contradicting Interpretation #8 
 
Trial ID: Dalfampridine (Ampyra) 
202 
 
FDAAA Status: Pre-FDAAA 
 
Sponsor: Acorda Therapeutics Inc 
 
FDA interpretation: Negative. "There were no statistically significant differences between any 
dose and placebo. Independent analyses by Dr. Joo-Yeon Lee of Pharmacometrics has shown no 









Published interpretation: Equivocal. “This phase 2 study suggests that a subgroup of patients, 
when treated with fampridine, experiences a clinically relevant improvement in walking ability, 
which is sustained for at least 14 weeks.” (91) 
 
Publication Bias 
  Pre-FDAAA, positive trials were more likely to be published (RR=1.52; 95% 
Confidence Interval [CI]=1.17-1.99; P=0.002) and published without misleading 
interpretations (RR=2.47; Cl=1.57-3.73; p<0.001) than those with non-positive results. In 
contrast, post-FDAAA, positive trials were equally likely to have been published (RR=1; 
Cl=1-1, p=NA) and published without misleading interpretations (RR=1.20; Cl=0.84-
1.72; p=0.30). The likelihood of publication bias pre-FDAAA vs. post-FDAAA was 
greater for publication of positive vs. non-positive trials (RRR=1.52; Cl=1.16-1.99; 
p=0.002) and for publication without misleading interpretations (RRR=2.06, Cl=1.17-











Study Findings & Prior literature 
  In this retrospective cohort study of 142 trials supporting the approval of 37 
neuropsychiatric therapeutics approved by the FDA between 2005 and 2014, post-
FDAAA trials were uniformly registered, reported results, published, and published 
without misleading interpretations. As compared to pre-FDAAA trials, proportions of 
trials that were registered and reporting results on ClinicalTrials.gov were significantly 
higher and the degree of publication bias was lower. Our results suggest that FDAAA 
likely contributed to improving the registration, results reporting, and publication of 
clinical trials supporting FDA approval of new drugs used to treat neuropsychiatric 
indications, although other factors may also have been in play.  
  Prior work examining similar clinical trials supporting FDA approval of new drugs 
in 2012, many of which were completed before FDAAA as enacted, found 57% were 
registered and 20% reported results on ClinicalTrials.gov. (41)  Among trials supporting 
approval of neuropsychiatric drugs, we found similar rates among pre-FDAAA trials, 
63% and 10%, but also show that among post-FDAAA trials, 100% were registered and 
reported results. A study involving trials supporting FDA approval of cardiovascular and 
diabetic drugs showed a similar association between FDAAA and trial registration and 
results reporting. (80) 
  As discussed previously, earlier studies have consistently demonstrated significant 
publication bias: positive trials are more likely to be published and published accurately 
or completely than non-positive trials. In our study, such publication bias was observed 








addition, overall rates of clinical trial publication were quite high, challenging the 
assumption that selective publication is worse among clinical trials of neuropsychiatric 
drugs than for other types of drugs.  Our findings have important implications for 
understanding the impact of FDAAA, for developing future strategies to improve 
selective publication and outcome reporting more broadly, and for the practice of 
evidence-based medicine.  
 
Implication for Understanding the Impact of FDAAA 
  There is likely a causal relationship between the enactment of FDAAA and the 
improved rates of registration and results reporting given the strength of the association, 
consistency of the association across different types of trials, existence of a temporal 
relationship, and high degree of plausibility. When we examined the relationship between 
FDAAA status with registration status and the relationship between FDAAA status with 
results reporting status using the two tailed Fisher Exact test, the p-Value was less than 
0.001 in both cases. Studies evaluating trials for cardiovascular and diabetic drugs 
showed the similar results. Considering that FDAAA explicitly required registration and 
results reporting and has the power to fine the sponsors $11,569 for each day a trial 
remains unreported following a 30-day notification period, it is reasonable to anticipate 
that there is  high degree of compliance for trials that were initiated after the FDAAA 
enactment. Other changes might also be contributory. For example, trials involving 
patients with serious and life threatening illnesses and pediadiatric patients were required 
to register according to FDAMA1997 and according to guidelines issued by the FDA for 
the pharmaceutical industry practice as early as 2004. (92). The ICMJE recommendation 








prospective trial registration. However, as previously discussed, only the 11 members of 
ICMJE were required to comply with ICMJE, while other journals follow the 
recommendation on a voluntary bassis. When surveyed, editors were willing to consider 
the publication of unregistered trials due to many factors: “not wanting to lose out to rival 
journals, not wanting to reject otherwise sound articles or submissions from developing 
countries, and perceptions that such policies were not relevant to all journals.” (93)  
The impact of FDAAA on reducing publication bias is less clear because FDAAA 
does not regulate medical journals directly. Our results at least provided a positive 
outlook. Post-FDAAA trials, regardless of the results, were all published. Publication 
bias was not detectable among the post-FDAAA trials and represents a significant 
improvement compared to the pre-FDAAA trials.  
 
Implications for Future Policy Development 
  FDAAA applies only to trials of medical products regulated by the FDA. But the 
practice of medicine includes not only the use of medical products to improve patient 
outcomes, but also behavioral, surgical and other procedural interventions, as well as 
health system interventions. To ensure that the medical literature is as unbiased and 
representative as is possible, rules and regulations like FDAAA, which mandate 
registration and results reporting in a publicly accessible database but also apply to all 
clinical research and health system studies, may be an effective strategy to promote 
comprehensive registration, results reporting, and publication. 
 








  The sponsors and investigators have published all of the Post-FDAAA clinical 
trials supporting the FDA’s decision to approve new drugs treating neurologic and 
psychiatric conditions and there were no negative trials misleadingly published to 
encourage positive interpretation. Evidence-based practice regarding the use of these 
drugs will be less affected by publication bias. However, it is uncertain whether this will 
improve the practice of medicine for several reasons. One, the “effective publication 
rate,” as perceived by clinicians and patients, may be lower because the publications for 
some trials were difficult to locate and were only found using specific trial data in 
multiple search engines. Two, the pharmaceutical companys, supported usually by large 
marketing departments have other ways to “advertise” their expensively made products, 
to incentivize physicians to prescribe the newer and more expensive drugs over the older 
or cheaper drugs. Lastly, it is unclear that EBM is itself the appropriate framework for 
medical decision making. The chasm between the RCT-based formula to providing care 
to patients, each with their unique circumstances in resource-constrained environments, is 
vast.  
 
  Limitations 
  Several factors should be considered in the interpretation of our findings. First, our 
study is cross-sectional and can only establish associations, not causality. Other reasons 
beyond FDAAA, including academic advocacy for clinical trial data transparency, may 
have accounted for trial sponsors’ and investigators’ decision to register, report results 
and publish the findings of the clinical trials. More studies are needed to disentangle the 
impact of FDAAA on clinical trial registration, results reporting, and publication from 








registration policy, although it’s not clear that this policy would impact either results 
reporting or publication. Second, we limited our search of trial registration to 
ClinicalTrials.gov. It is possible that trials conducted pre-FDAAA used other registers. 
Third, for trials determined to be unregistered or unpublished, we did not contact sponsor 
companies for confirmation. Fourth, our sample is limited to phase II and III trials 
supporting neuropsychiatric drugs and the sample size of post-FDAAA trials, at 41, is 
relatively small. Fifth, our study was focused on pre-marketing phase II and III trials 
evaluating neuropsychiatric drugs successfully approved by the FDA. Our findings may 
not be generalized to phase I and phase IV post marketing trials, trials evaluating drugs 
that were not approved by the FDA, as well as trials for other types of drugs for which 
the registration and publication have yet to be characterized. Finally, our study was 
focused on the reporting and publication of trials’ primary results and did not examine 
reporting or publication of secondary and safety outcomes. 
 
Conclusions 
  For clinical trials supporting the FDA approval of new drugs for 
neuropsychiatric indications, the proportions of trials that were registered and reporting 
results on ClinicalTrials.gov were significantly higher and publication bias was 
significantly lower after the passage of FDAAA in 2007, suggesting that FDAAA likely 
contributed to the reduction of selective registration and results reporting and to 
mitigating publication bias. These findings have important implications for understanding 
the potential impact of FDAAA, along with other initiatives that may have improved 
research reporting, and for developing future strategies to improve selective publication 
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Figures, Titles, and Legends 
 
Figure 1.  Identification of Trials Reviewed by the FDA for New Drug Applications with 
Neuropsychiatric Indications, 2005-2014 
 
 
Legend: Flow chart depicting the process of selecting efficacy trials reviewed by the 
FDA for the approval of new drug with neuropsychiatric indicatioons between 2005-










Figure 2 Registration and Results Reporting Status of Trials Supporting FDA Indications 
by FDAAA applicability, 2005-2014 
 
 
Legend: Post-FDAAA trials were significantly more likely to be registered (100% vs 
64%; P<0.001) and report results (100% vs 10%; P<0.001) than pre-FDAAA. Outcomes 




















Figure 3. Publication Status and Publication-FDA Agreement of Neuropsychiatric Trials 
by FDAAA applicability and by Trial Results 
 
 
Legend: Overall, more Post-FDAAA trials were published (100% vs 90%; P=0.06) and 
the publication were in agreement with the FDA’s interpretation (98% vs. 93%; P=0.28), 
but neither the outcomes were significant. When stratified by results, trials with positive 
were all published during both pre- (72 of 72) and post-FDAAA (35 of 35). When trials 
with negative results were examined in isolation, the publication rate was significantly 
higher after FDAAA as compared to before (5 of 5 vs 5 of 13; P=0.04). There were not 
enough equivocal trials to draw comparison. All comparisons were based on two-tailed 
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